Is there a head-to-head trial comparing these two drugs for weight loss?

Not yet. An indirect comparison matched patients across two separate clinical trials, but this is less reliable than a direct comparison. A separate trial compared them directly in people with type 2 diabetes using a lower dose of oral semaglutide (14mg instead of 25mg). A direct obesity head-to-head would give clearer answers.

Why does Oral Wegovy require fasting but Foundayo does not?

Oral semaglutide is a peptide — a large molecule that is fragile in the stomach. The pill contains a special absorption enhancer (SNAC) that works best on an empty stomach. Orforglipron is a small molecule that absorbs well regardless of food. This is a fundamental chemistry difference, not a dosing preference.

Does either pill have proven cardiovascular benefits?

Not as weight-loss pills yet. Semaglutide’s heart evidence comes from the weekly injection: the SELECT trial followed 17,604 adults with established heart disease and overweight or obesity for a median of about 40 months and found a 20% reduction in heart attacks, strokes, and cardiovascular death. It did not test the tablet. Orforglipron does not yet have heart outcomes data, though blood pressure improvements have been observed in its trials.

Can I switch between these two drugs?

Potentially, but any switch should be discussed with your doctor. They are different drugs with different dose escalation schedules, and your doctor would typically have you restart the dose titration process when switching. A separate 52-week study (ATTAIN-MAINTAIN) followed people switching from injectable Wegovy or Zepbound to orforglipron and found they kept nearly all of their prior weight loss — a difference of only about 2 lbs over a year. There is no published data yet on switching directly between the two oral pills.

Which one has more side effects?

Both cause similar stomach side effects (nausea, diarrhea, vomiting), especially during dose escalation. In an indirect comparison, Foundayo showed higher quit rates. In a head-to-head diabetes trial (different doses), Foundayo had roughly double the quit rate (9.7% vs 4.9%).

Will insurance cover either of these?

Coverage varies widely by plan. Both manufacturers offer self-pay programs. Foundayo offers $25/month with eligible commercial insurance and may be available through Medicare Part D from July 2026 at approximately $50/month. Check with your specific insurer for current coverage.

Wegovy Pill vs Foundayo: Oral GLP-1s

Weight loss at maximum dose

From separate clinical trials — no direct head-to-head comparison exists for obesity.

Oral Wegovy(Semaglutide pill)16.6%(~40 lbs)

Foundayo(Orforglipron)12.4%(~30 lbs)

For a 240 lb person. Oral Wegovy figure is with full adherence to dosing instructions. Foundayo's figure is for the highest trial dose (36 mg of the trial capsule, shown in the FDA label as the 17.2 mg tablet) among people who kept taking it. Individual results vary substantially.

Oral Wegovy and Foundayo compared on weight loss, dosing rules, cost, heart benefit and quit rate
Attribute	Oral Wegovy	Foundayo
Weight loss	~16.6%	~12.4%
When to take	Morning, empty stomach	Any time of day
Food restrictions	30-min fast before food	None
Cost (self-pay)	$149–$299/mo, by dose	$149–$349/mo
Heart benefit	Yes (proven)	Not yet studied
Quit rate (side effects)	~6.9%	~8%
FDA approved	December 2025	April 2026
Manufacturer	Novo Nordisk	Eli Lilly

~40 lbs vs ~30 lbs for a 240 lb person

The real difference: daily routine

Oral Wegovy

1. Wake up, take pill with small sip of water
2. Wait 30 minutes — no food, drink, or other pills
3. Then eat breakfast and take other medications

This routine is strict — skipping it reduces the drug's effectiveness.

Foundayo

1. Take pill whenever you want
2. That's it. No timing restrictions.

No food-timing restrictions to work around. Good for variable schedules or shift work.

Important: No head-to-head obesity trial exists between these two drugs. The weight loss figures come from separate clinical trials with different designs. An indirect comparison funded by Novo Nordisk (Oral Wegovy's maker) found oral semaglutide showed about 3 percentage points more weight loss with fewer people quitting. A separate trial in type 2 diabetes (using a lower semaglutide dose) found orforglipron performed better. Different populations, different doses, different results.

Monthly cost

Self-pay / manufacturer programs. Insurance coverage varies.

Oral Wegovy(Highest dose)$149–$299/mo

Foundayo(Highest dose)$149–$349/mo

At the starting dose, both cost $149. At the highest dose, Foundayo runs to $349/mo versus $299/mo for Oral Wegovy. Both offer $25/mo with eligible commercial insurance; Foundayo's Medicare Part D coverage is expected from July 2026 (~$50/mo).

Side effects comparison

From each drug's clinical trials. Both are oral GLP-1s — side effects are similar but not identical.

Nausea

Oral Wegovy44%

Foundayo33%

Diarrhea

Oral Wegovy18%

Foundayo18%

Vomiting

Oral Wegovy20%

Foundayo16%

Constipation

Oral Wegovy10%

Foundayo10%

Quit due to side effects

Oral Wegovy5%

Foundayo8%

Oral Wegovy has higher nausea rates but fewer people quit. Both cause stomach side effects mostly during dose escalation (weeks 2–8).

The trade-offs side by side

Consider Oral Wegovy if you...

Want the higher average weight loss
Can commit to a strict morning routine
Value proven heart benefit
Prefer the lower cost at the highest dose ($299 vs $349)

Consider Foundayo if you...

Need flexibility — no food or timing rules
Have a variable schedule or shift work
Take other morning medications
Prefer starting at the same cost ($149/mo)

Prefer higher weight loss? Injections show more.

Tirzepatide injection (Zepbound): ~20.9% average weight loss. Semaglutide injection (Wegovy): ~14.9% with proven heart benefits. Both are weekly injections.

See the injection comparison →

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Clinical evidence — Oral Wegovy vs Foundayo

The weight loss figures above come from two separate trials (OASIS 4 and ATTAIN-1), an indirect cross-trial comparison (ORION), a head-to-head trial in type 2 diabetes at different doses (ACHIEVE-3), and the SELECT cardiovascular outcomes trial for semaglutide's heart-benefit claim. In OASIS 4, average weight loss on oral semaglutide 25 mg was 13.6% counting everyone who started (intent-to-treat), or 16.6% among people who kept taking it. In ACHIEVE-3 (1,698 adults with type 2 diabetes, 52 weeks), orforglipron at the 36 mg trial capsule dose was compared with oral semaglutide at the lower 14 mg diabetes dose: weight loss was 9.2% vs 5.3%.

OASIS 4 — Semaglutide (oral pill): 307 adults with obesity or overweight + at least 1 health condition, 64 weeks. New England Journal of Medicine, 2024. View source ↗
ATTAIN-1 — Orforglipron: 3,127 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2025. View source ↗
ORION — Oral Semaglutide vs Orforglipron: Population-adjusted matching of OASIS-4 (oral semaglutide 25mg) vs ATTAIN-1 (orforglipron, 36 mg trial capsule dose) trial participants, 64–72 weeks. Presented at Obesity Medicine Association (OMA) 2026, 2026. View source ↗
ACHIEVE-3 — Orforglipron vs Oral Semaglutide: 1,698 adults with type 2 diabetes (not obesity-specific), 52 weeks. The Lancet, 2026. View source ↗
SELECT — Semaglutide (injection): 17,604 adults with established cardiovascular disease and overweight or obesity (BMI 27 or higher), without type 2 diabetes, ~40 months (median). New England Journal of Medicine, 2023. View source ↗
ATTAIN-MAINTAIN — Orforglipron: Adults switching from injectable Wegovy or Zepbound to orforglipron, 52 weeks. Eli Lilly press release, 2025. View source ↗

Wegovy (semaglutide) tablets — FDA prescribing information — 6.9% of tablet-treated patients discontinued treatment due to adverse reactions, vs. 5.9% with placebo (section 6.1, adverse reactions) View source ↗

Not sure where to start? Our 2-minute quiz can help.

Take the quiz →

Built with agentic AI tools and not a substitute for medical advice

Last reviewed: September 2026

Was this page helpful?

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Prices shown are United States self-pay or list prices and vary by insurance and country.

Next step most people take

Compare All OptionsSee how medications, diet, exercise, and supplements compare Semaglutide (Wegovy)Pill vs injection, weight loss, cardiovascular data Orforglipron (Foundayo)Weight loss, convenience, cost, and how it works